Skip to main content

Impact of multiplex PCR respiratory panels on antimicrobial stewardship and clinical outcomes in hospitalized adults with pneumonia: a systematic review and meta-analysis

In brief

PCR panels shortened pneumonia antibiotic courses by 0.74 days, not significantly

Across six randomized trials involving 2,087 hospitalized adults with pneumonia, multiplex PCR-guided care was linked to 0.74 fewer antibiotic days on average, but the reduction was not statistically significant. The analysis also found no significant differences in other measured outcomes, including mortality and hospital stay; whether particular testing and implementation strategies improve care remains unclear.

Journal
Infection (Q1)
Published
9 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Chaehyun Ahn, Adam N Chanliongco, Andrew J Smith, Taylor D Steuber, Morgan Sperry
PMID
43002357
DOI
10.1007/s15010-026-03045-w

Why clinicians should know about it

  • Picked for Microbiology (medical) (top studies of the week, 15 November 2026): Systematic review of rapid multiplex PCR diagnostics and stewardship outcomes
  • Picked for Pulmonary and Respiratory Medicine (top studies of the week, 15 November 2026): Randomized evidence on pathogen panels and pneumonia treatment

Abstract

BACKGROUND: Inadequate empiric antimicrobial therapy increases mortality and healthcare costs. Rapid multiplex PCR respiratory panels can provide faster and more sensitive pathogen detection than conventional culture-based methods; however, interpretation may be limited by detection of colonizing organisms and resistance genes that do not always correspond to phenotypic resistance. Their impact on clinical outcomes and antimicrobial stewardship remains uncertain due to heterogeneous studies and clinical implementation strategies. This systematic review and meta-analysis evaluates the clinical value of these panels in hospitalized adults with pneumonia. METHODS: Following PRISMA guidelines, we searched MEDLINE, EMBASE, and the Cochrane Library through October 15, 2025, for randomized controlled trials (RCTs) comparing multiplex PCR-guided therapy with standard microbiological testing. The primary outcome was total antibiotic duration. Secondary outcomes included incidence of targeted/appropriate antimicrobial therapy, length of hospitalization, 1-month mortality, 1-month hospital readmission, and antibiotic-related adverse events. FINDINGS: The analysis included six RCTs involving 2,087 patients. Multiplex PCR-guided therapy showed a modest but non-significant reduction in antibiotic duration (MD -0.74 days; 95% CI: -2.28 to 0.79; p = 0.22). No statistically significant differences were found for secondary outcomes, including targeted or appropriate antimicrobial therapy, length of hospitalization, antibiotic-related adverse events, 1-month mortality, or 1-month hospital readmissions. CONCLUSIONS: Multiplex PCR panels provide rapid diagnostic data, but the available randomized evidence provides insufficient evidence that their implementation reduces total antibiotic duration or downstream clinical outcomes in patients with pneumonia. These findings do not exclude potential benefits in earlier antimicrobial optimization, which appear to depend on clinical context and implementation strategy.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.